Extracorporeal photochemotherapy - The Columbia Presbyterian experience

Photodermatology Photoimmunology and Photomedicine

Volumn 18, Issue 5, 2002, Pages 232-237

  Knobler, Elizabeth ^a   Warmuth, Ingrid ^a   Cocco, Carolyn ^b   Miller, Barbara ^c   Mackay, Julian ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Johnson and Johnson PRD   (United States)

^c NONE

Author keywords

Cutaneous T cell lymphoma; Extracorporeal photochemotherapy; Photopheresis

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; ETRETINATE; LACTATE DEHYDROGENASE; METHOTREXATE; METHOXSALEN; PREDNISONE; PSORALEN; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL ARTICLE; COLOMBIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CUTANEOUS T CELL LYMPHOMA; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DRUG TOLERABILITY; ERYTHRODERMA; FEMALE; HEMATOMA; HUMAN; HYPOTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE HOMING; MALE; MANTEL HAENSZEL TEST; MEDICAL RECORD; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PUVA; RADIATION RESPONSE; RETROSPECTIVE STUDY; SEPTICEMIA; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; CHI SQUARE DISTRIBUTION; MIDDLE AGED; PHOTOCHEMOTHERAPY; PREDICTION AND FORECASTING; REMISSION; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOPHERESIS; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0036808945     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0781.2002.02762.x     Document Type: Article

References (35)

1. Bunn P, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep 1979; 63: 725-728.
2. Foss F, Sausville E. Prognosis and staging of cutaneous T-cell lymphoma. Hematol Oncol Cl N Am 1995; 9: 1011-1019.
3. Jorg B, Kerl H, Thiers GH, Brocker EB, Burg G. Therapeutic approaches in cutaneous lymphoma. Dermatol Clin 1994; 12: 433-441.
4. Hurst RE. Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs 2000; 1: 514-523.
5. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin) caps for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 649-52.
6. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19: 376-388.
7. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma. N Engl J Med 1987; 316: 297-303.
8. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427-433.
9. Koh HK, Davis BE, Meola T, Lim HW. Extracorporeal photochemotherapy for the treatment of 34 patients with cutaneous T-cell lymphoma (CTCL). J Invest Dermatol 1994; 102: 567.
10. Duvic M, Hester J, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1999; 35: 573-579.
11. Stevens SR, Bowen GM, Duvic M, et al. Effectiveness of photopheresis in Sezary Syndrome. Arch Dermatol 1997; 135: 995-997.
12. Demierre MF, Foss F, Koh H. Proceedings of the International Consensus Conference on Cutaneous T-Cell Lymphoma (CTCL): Treatment Recommendations. J Am Acad Dermatol 1997; 36: 460-466.
13. Herrick C, Heald P. The dynamic interplay of malignant and benign T cells in cutaneous T-cell lymphoma. Dermatol Clinics 1997; 15: 149-157.
14. Heald P, Perez M, Christiensen I, McKiernan G, Edelson R. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale New Haven Hospital Experience. Yale J Biol Med 1989; 62: 629-638.
15. Rook A, Cohen J, Lessin S, Vowels B. Therapeutic applications of photopheresis. Dermatol Clinics 1993; 11: 339-347.
16. Jiang SB, Dietz SB, Kim M, Lim HW. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7 year experience. Photodermatol, Photoimmunol, Photomed 1999; 15: 161-165.
17. Bisaccia E, Gonzalez J, Palangio M, Schwartz J, Klainer A. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. J Am Acad Dermatol 2000; 43: 263-271.
18. Knobler R. Extracorporeal photochemotherapy - present and future. Vox Sang 2000; 78 (Suppl 2): 197-201.
19. Lim HW, Edelson R. Photopheresis for the treatment of cutaneous T-cell Lymphoma. Hematol Oncol Clin N Am 1995; 9: 1117-1126.
20. Oiven A, Shechter Y. Extracorporeal photopheresis: a review. Blood Rev 2001; 15: 103-108.
21. Russo G, Mullen C. Cutaneous and noncutaneous disorders treated with extracorporeal photopheresis. Int J Dermatol 2001; 40: 89-100.
22. Tambur AR, Ortegel JW, Morales A, Klingemann H, Gebel HM, Tharp M. Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis. Transplant Proc 2000; 32: 747-748.
23. Rook A, Suchinn K, Kao D. Photopheresis: clinical applications and mechanism of action. J Inv Dermatol 1999; 4: 85-90.
24. Berger CL, Xu AL, Hanlon D, et al. Induction of huma tumor-loaded dendritic cells. Int J Cancer 2001; 91: 438-447.
25. Rook AH, Gottlieb SL, Wolfe JT, et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clinic Exp Immunol 1997; 107 (Suppl 1): 16-20.
26. DiRenzo M, Rubegni P, DeAloe G, et al. Extracorporeal photochemotherapy restores TH1/TH2 inbalance in patients with early stage cutaneous T-cell lymphoma. Immunology 1997; 92: 99-103.
27. Yoo EK, Cassin M, Lessin SR, Rook AH. Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Derm 2001; 45: 208-216.
28. Vowels BR, Cassin M, Boufal MH, Walsh LJ, Rook AH. Extracorporeal photochemotherapy induces the production of tumor necrosis factor alpha by monocytes. Implication for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol 1992; 122: 686-692.
29. Wolfe JR, Lessin St SinghAh, Rook AH. Review of immunomodulation photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. Artif Organs 1994; 18: 888-897.
30. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996; 107: 235-242.
31. Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft versus host disease patients. Br J Haematol 1999; 107: 707-711.
32. Russell-Jones R, Whitaker S. Sezary Syndrome: diagnostic criteria and therapeutic options. Sem Cut Med Surg 2000; 19: 100-108.
33. Armus S, Keyes B, Cahill C, et al. Photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1990; 23: 898-902.
34. Salvaneschi L, Perotti C. Adverse effects associated with extracorporeal photochemotherapy. Transfusion 2000; 40: 121.
35. Suchin K, Cassin M, Washko R, et al. Extracorporeal photochemotherapy does not suppress T or B cell responses to novel or recall antigens. J Am Acad Dermatol 1999; 41: 980-986.